Rowlandmiller & Partners’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.34M Buy
14,748
+2
+0% +$685 0.97% 26
2026
Q1
$5.19M Sell
14,746
-1,032
-7% -$368K 1.05% 25
2025
Q4
$5.16M Sell
15,778
-15
-0.1% -$4.76K 1% 26
2025
Q3
$4.46M Sell
15,793
-1,680
-10% -$487K 0.88% 31
2025
Q2
$4.88M Sell
17,473
-115
-0.7% -$32.6K 1.01% 28
2025
Q1
$5.48M Buy
17,588
+40
+0.2% +$11.8K 1.15% 24
2024
Q4
$4.57M Sell
17,548
-567
-3% -$168K 0.96% 30
2024
Q3
$5.84M Sell
18,115
-290
-2% -$94.9K 1.19% 24
2024
Q2
$5.75M Sell
18,405
-310
-2% -$91.1K 1.25% 23
2024
Q1
$5.32M Sell
18,715
-76
-0.4% -$22.2K 1.12% 30
2023
Q4
$5.41M Sell
18,791
-30
-0.2% -$8.17K 1.24% 26
2023
Q3
$5.06M Sell
18,821
-89
-0.5% -$22.2K 1.25% 26
2023
Q2
$4.2M Sell
18,910
-65
-0.3% -$15.1K 0.99% 32
2023
Q1
$4.59M Sell
18,975
-307
-2% -$75.4K 1.11% 31
2022
Q4
$5.05M Buy
19,282
+355
+2% +$95.2K 1.25% 26
2022
Q3
$4.27M Buy
18,927
+5
+0% +$1.21K 1.15% 30
2022
Q2
$4.6M Sell
18,922
-30
-0.2% -$7.35K 1.18% 28
2022
Q1
$4.58M Sell
18,952
-562
-3% -$129K 1.06% 30
2021
Q4
$4.39M Buy
19,514
+59
+0.3% +$12.5K 0.98% 32
2021
Q3
$4.59M Buy
19,455
+110
+0.6% +$25.3K 1.56% 19
2021
Q2
$4.72M Hold
19,345
1.16% 30
2021
Q1
$4.81M Sell
19,345
-115
-0.6% -$27.4K 1.26% 28
2020
Q4
$4.47M Buy
19,460
+191
+1% +$44K 1.28% 27
2020
Q3
$3.91M Sell
19,269
-186
-1% -$46.1K 1.57% 17
2020
Q2
$4.59M Buy
19,455
+186
+1% +$42.4K 1.56% 19
2020
Q1
$3.91M Sell
19,269
-664
-3% -$145K 1.57% 17
2019
Q4
$4.81M Buy
19,933
+885
+5% +$195K 1.49% 23
2019
Q3
$3.69M Buy
19,048
+462
+2% +$88.7K 1.25% 29
2019
Q2
$3.43M Buy
18,586
+175
+1% +$31.3K 1.19% 32
2019
Q1
$3.5M Buy
18,411
+97
+0.5% +$18.5K 1.25% 29
2018
Q4
$3.57M Sell
18,314
-230
-1% -$44.9K 1.44% 23
2018
Q3
$3.84M Sell
18,544
-168
-0.9% -$33.1K 1.39% 27
2018
Q2
$3.45M Sell
18,712
-445
-2% -$78.7K 1.34% 24
2018
Q1
$3.28M Sell
19,157
-245
-1% -$45K 1.3% 25
2017
Q4
$3.39M Buy
19,402
+300
+2% +$53.1K 1.33% 26
2017
Q3
$3.55M Sell
19,102
-522
-3% -$92.5K 1.48% 25
2017
Q2
$3.39M Sell
19,624
-9
-0% -$1.46K 1.43% 25
2017
Q1
$3.22M Sell
19,633
-68
-0.3% -$11.3K 1.42% 26
2016
Q4
$2.88M Buy
19,701
+796
+4% +$120K 1.3% 27
2016
Q3
$3.15M Sell
18,905
-365
-2% -$61.7K 1.46% 25
2016
Q2
$2.94M Sell
19,270
-216
-1% -$33.6K 1.35% 26
2016
Q1
$2.92M Buy
19,486
+7
+0% +$1.04K 1.38% 24
2015
Q4
$3.07M Sell
19,479
-16
-0.1% -$2.52K 1.56% 19
2015
Q3
$2.64M Sell
19,495
-562
-3% -$88.6K 1.4% 23
2015
Q2
$3.08M Sell
20,057
-627
-3% -$100K 1.53% 22
2015
Q1
$3.23M Sell
20,684
-1,144
-5% -$180K 1.61% 21
2014
Q4
$3.48M Buy
+21,828
New +$3.4M 1.69% 21

Other funds holding AMGN

Rowlandmiller & Partners's AMGN Position: Q2 2026 in Review

Rowlandmiller & Partners increased its Amgen (AMGN) stake by 0.01% in Q2 2026, buying an estimated $685 and bringing the position to 14,748 shares worth $5.34M. The position accounts for 0.97% of the portfolio, ranked #26.

Rowlandmiller & Partners first reported a position in AMGN in Q4 2014 and has held it in 47 quarters since. The position peaked at $5.84M in Q3 2024. 1,543 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Rowlandmiller & Partners held 14,748 shares of Amgen worth $5.34M as of Q2 2026.
  • Rowlandmiller & Partners bought 2 Amgen shares in Q2 2026, an estimated $685.
  • Amgen made up 0.97% of Rowlandmiller & Partners's portfolio in Q2 2026, its #26 holding.
  • Rowlandmiller & Partners first reported a position in Amgen in Q4 2014 and has held it in 47 quarters since.
  • Rowlandmiller & Partners's Amgen position peaked at $5.84M in Q3 2024.
  • 1,543 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Rowlandmiller & Partners's 13F filing for Q2 2026, filed 23 Jul 2026.